Company dossier
Himadri Speciality Chemical Limited
Current pulse
Pattern-matched earnings signal
Record revenue, EBITDA, PAT and margin expansion support the read; lower volume and a dense commissioning program keep the stance at HOLD pending execution evidence.
Record earnings and mix-led margin expansion outweighed lower volume, with commissioning now the main execution test.
Sales volume fell 5.9% YoY and 2.8% QoQ.
Q1 FY2027 earnings call
Dossier map
Record earnings and mix-led margin expansion outweighed lower volume, with commissioning now the main execution test.
Revenue ₹1.4K Cr | PAT ₹228.43 Cr
This layer will track order book, execution runway, capex, capacity and pipeline as company-specific fields are populated.
Latest on-record topic: Q4 and FY2026 results, speciality carbon black, coal-tar pitch, battery materials, Birla Tyres, capital allocation and FY2027 execution milestones
Chemicals needs explicit government, rates, commodity, FX and demand sensitivity mapping.
Evidence links, management clips, filings, transcripts and source confidence are shown at the bottom of the dossier.